Venetoclax-based therapy in acute myeloid leukemia had a 6.5% incidence of MACE, which independently predicted inferior overall survival (adjusted HR 2.75; 95% CI 1.41-5.35).
Cohort (n=214)
No
What is the incidence and impact of major adverse cardiac events in patients with newly diagnosed acute myeloid leukemia receiving venetoclax-based therapy?
Major adverse cardiac events occur in 6.5% of newly diagnosed AML patients treated with venetoclax and are associated with significantly worse overall survival.
Effect estimate: adjusted HR 2.75 (95% CI 1.41-5.35)
p-value: p=<0.01
BACKGROUND: Venetoclax, a potent B-cell leukemia/lymphoma-2 inhibitor, is an antineoplastic agent used in various hematologic malignancies, including acute myeloid leukemia (AML). The aim of the study is to evaluate the incidence, risk factors, and outcomes of major adverse cardiac events (MACEs) among patients with newly diagnosed AML receiving venetoclax-based therapy. METHODS: We conducted a retrospective, single-center cohort study of 214 patients with newly diagnosed AML treated with venetoclax. MACE was defined as a composite of new-onset heart failure, heart failure exacerbation requiring hospitalization, myocardial infarction/coronary revascularization, or stroke/transient ischemic attack during active venetoclax-based therapy. The Fine-Gray subdistribution hazard model determined the association between baseline clinical characteristics and MACEs, with noncardiovascular death as a competing risk. A Cox proportional hazard model determined the association between time-dependent MACEs and overall survival. RESULTS: <0.01). Time-dependent MACE was independently associated with inferior overall survival (adjusted HR, 2.75 95% CI, 1.41-5.35). CONCLUSIONS: In conclusion, MACE is a clinically significant event that occurs in 6.5% of patients with AML treated with venetoclax and is a higher-risk event for patients with secondary AML or treatment-related AML.
Selvakumar et al. (Wed,) conducted a cohort in Acute myeloid leukemia (AML) (n=214). Venetoclax-based therapy was evaluated on Major adverse cardiac events (MACEs) defined as new-onset heart failure, heart failure exacerbation requiring hospitalization, myocardial infarction/coronary revascularization, or stroke/transient ischemic attack (adjusted HR 2.75, 95% CI 1.41-5.35, p=<0.01). Venetoclax-based therapy in acute myeloid leukemia had a 6.5% incidence of MACE, which independently predicted inferior overall survival (adjusted HR 2.75; 95% CI 1.41-5.35).